To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery.
Azevedo H, Renesto PG, et al. Hum Genomics 2016; 10(1): 2.
Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial.
Bonani M, Frey D, et al. American Journal of Transplantation 2015;16(6):1882-91
Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
Carmellini M, Garcia V, et al. Journal of Nephrology 2015; 28(5): 633-639.
Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.
Hricik DE, Formica RN, et al. Journal of the American Society of Nephrology 2015; 26(12): 3114-3122.
A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation.
Shuker N, Bouamar R, et al. American Journal of Transplantation 2016;16(7):2085-96
Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
Thierry A, Lemeur Y, et al. Transplant International 2016; 29(1): 23-33.
Effect of omega-3 on hepatic regeneration in adult living donors undergoing hepatic resections for liver transplantation: A randomized controlled trial.
Ibrahim ES, Saleh SM, et al. Journal of Critical Care 2016; 31(1): 157-162.
A Randomized Controlled Trial of a Mobile Health Intervention to Promote Self-Management after Lung Transplantation.
DeVito Dabbs A, Song MK, et al. American Journal of Transplantation 2016; 16(7): 2172-80
Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
Ruttens D, Verleden SE, et al. American Journal of Transplantation 2016; 16(1): 254-261.
Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients.
Fernandez-Ruiz M, Humar A, et al. Vaccine 2015; 33(51): 7176-7182